Advertisement

Replacing HMG/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial

Published:October 24, 2019DOI:https://doi.org/10.1016/j.rbmo.2019.10.008

      Abstract

      Research question

      The cost of IVF treatment remains high, among other factors because of the medication needed for ovarian stimulation. This study investigated the effect of using low-dose human chorionic gonadotrophin (HCG) for the second phase of follicular maturation after corifollitropin alfa induction, to replace the more expensive, either recombinant or human menopausal gonadotrophin (HMG), on the cost of ovarian stimulation.

      Design

      One hundred and five patients were randomly divided into two groups: patients in the HCG group (n = 50) received low-dose HCG from Day 7 until the diameter of at least three follicles reached 17 mm or more, while patients in the FSH group (n = 55) received conventional ovarian stimulation with highly purified HMG injections.

      Results

      The clinical pregnancy rate in the HCG group was 38% higher than in the FSH group (number needed to treat, NNT = 13). The cost per pregnancy needed for ovarian stimulation was reduced from €4902 in the FSH group to €2684 in the HCG group. Hence, the cost of ovarian stimulation medication to obtain 10 pregnancies using the conventional FSH protocol is sufficient to attain 18 pregnancies when applying the low-dose HCG protocol.

      Conclusion

      This study provides evidence that using HCG instead of HMG/FSH for ovarian stimulation results in a significant reduction in the cost of IVF with, at least, an equivalent pregnancy rate.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Reproductive BioMedicine Online
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alper M.M.
        • Smith L.P.
        • Sills E.S.
        Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.
        J. Exp. Clin. Assist. Reprod. 2009; 6: 3
        • Ascoli M.
        • Fanelli F.
        • Segaloff D.L.
        The Lutropin/Choriogonadotrophin Receptor, A Perspective.
        Endocr. Rev. 2002; 23: 141-174
        • Baczkowski T.
        • Kurzawa R.
        • Głabowski W.
        Methods of embryo scoring inin vitro fertilization. Reprod.
        Biol. 2004; 4: 5-22
        • Blockeel C.
        • Verpoest W.
        • Stoop D.
        • Haentjens P.
        • De Vos M.
        • Devroey P.
        Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
        Hum. Reprod. 2009; 24: 2910-2916
      1. Comhaire, F., De Clerck, K., Vanden Berghe, W., Devriendt, G., Osmanagaoglu, K., Decleer, W., In press. The effect of different nutraceuticals in women undergoingin vitro fertilization: a controlled randomized study. Facts, Views and Vision in Obgyn (in press)

        • Damewood M.D.
        • Shen W.
        • Zacur H.A.
        • Schlaff W.D.
        • Rock J.A.
        • Wallach E.E.
        Disappearance of exogenously administered human chorionic gonadotrophin.
        Fertil. Steril. 1989; 52: 398-400
        • Devroey P.
        • Boostanfar R.
        • Koper N.P.
        • Mannaerts B.M.J.L.
        • Ijzerman-Boon P.C.
        • Fauser B.C.J.M.
        A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
        Hum. Reprod. 2009; 24: 3063-3072
        • Filicori M.
        • Cognigni G.E.
        • Tabarelli C.
        • Pocognoli P.
        • Taraborrelli S.
        • Spettoli D.
        • Ciampaglia W.
        Stimulation and growth of antral ovarian follicles by selective LH activity administration in women.
        J. Clin. Endocrinol. Metab. 2002; 87: 1156-1161
        • Filicori M.
        • Cognigni G.E.
        • Troilo E.
        • Parmegiani L.
        • Gamberini E.
        • Roset B.
        Efficacy of low-dose human chorionic gonadotrophin alone to complete controlled ovarian stimulation.
        Fertil. Steril. 2005; 84: 394-401
        • Jeppesen J.V.
        • Kristensen S.G.
        • Nielsen M.E.
        • Humaidan P.
        • Dal Canto M.
        • Fadini R.
        • Schmidt K.T.
        • Ernst E.
        • Yding Andersen C.
        LH-Receptor Gene Expression in Human Granulosa and Cumulus Cells from Antral and Preovulatory Follicles.
        J. Clin. Endocrinol. Metab. 2012; 97: 1524-1531
        • Leão Rde B.
        • Esteves S.C.
        Gonadotrophin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.
        Clinics. (Sao Paulo). 2014; 69: 279-293
        • Martins W.
        • Vieira A.
        • Figueiredo J.
        • Nastri C.
        FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques.
        Cochrane Database Syst. Rev. 2013; 28 (Review)CD010042https://doi.org/10.1002/14651858.CD010042.pub2
        • Ombelet W.
        The Walking Egg Project: Universal access to infertility care–from dream to reality.
        Facts views Vis. ObGyn. 2013; 5: 161-175
        • Orvieto R.
        HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter?.
        RBMO. 2019; (2019.08.010)
        • Serafini P.
        • Yadid I.
        • Motta E.L.A.
        • Alegretti J.R.
        • Fioravanti J.
        • Coslovsky M.
        Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotrophin forin vitro fertilization: a prospective, randomized trial.
        Fertil. Steril. 2006; 86: 830-838
        • Strowitzki T.
        • Seehaus D.
        • Korell M.
        • Hepp H.
        Low-dose FSH stimulation in polycystic ovary syndrome: Comparison of 3 FSH-preparations.
        Exp. Clin. Endocrinol. Diabetes. 2009; 106: 435-439
        • Van Horne A.K.
        • Bates G.W.
        • Robinson R.D.
        • Arthur N.J.
        • Propst A.M.
        Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotrophin compared with rFSH alone for ovarian stimulation forin vitro fertilization.
        Fertil. Steril. 2007; 88: 1010-1013
        • Zegers-Hochschild F.
        • Adamson G.D.
        • Dyer S.
        • Racowsky C.
        • De Mouzon J.
        • Sokol R.
        • Rienzi L.
        • Sunde A.
        • Schmidt L.
        • Cooke I.D.
        • Simpson J.L.
        • Van der Poel S.
        The international glossary on infertility and fertility care, 2017.
        Hum. Reprod. 2017; 32: 1786-1801

      Biography

      After his training in Leuven, London, Bremen and Bonn, Dr Wim André Emile Decleer set up an IVF centre at the Jan Palfijn Hospital in Gent in 1991. The fertility centre is now one of the biggest in Belgium.
      Key message
      This pragmatic prospective randomized trial demonstrates the possibility of reducing the costs of stimulation for IVF by replacing FSH in the second half of the proliferation phase by low-dose HCG, without reducing the chances of pregnancy.